DRKS00021440招募中不适用
Analysis of the C1-Esterase Inhibitor at patients with COVID-19 as a biomarker for the course of the disease
niversitätsklinikum Gießen und Marburg0 个研究点目标入组 50 人开始时间: 2021年1月28日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 Years 至 one（—）
- 性别
- All
入选标准
- •positive PCR SARS-CoV-2; treatment on intensive care unit or home quarantine
排除标准
- •age < 18 years
研究者
相似试验
已完成
1 期
A Study to Evaluate the Clinical Pharmacology and Safety of C1-esterase Inhibitor Administered by the Subcutaneous RouteHereditary Angioedema Types I and IINCT01576523CSL Behring18
尚未招募
不适用
In vivo effects of C1-esterase inhibitor on innate immune response during endotoxemia in human.sepsisinflammation1002766510002252NL-OMON32783niversitair Medisch Centrum Sint Radboud10
进行中（未招募）
1 期
A study of the effect of the drug C1-esterase inhibitor on the immune system in patients after administration of endotoxin.Inflammation, SIRS and endotoxemiaMedDRA version: 15.1Level: PTClassification code 10061218Term: InflammationSystem Organ Class: 10018065 - General disorders and administration site conditionsMedDRA version: 15.1Level: LLTClassification code 10060412Term: Septicaemia due to Escherichia coli (E. coli)System Organ Class: 10021881 - Infections and infestationsMedDRA version: 15.1Level: LLTClassification code 10051553Term: Complement factor C1System Organ Class: 100000004848MedDRA version: 15.1Level: PTClassification code 10040047Term: SepsisSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 15.1Level: LLTClassification code 10062357Term: SIRSSystem Organ Class: 10018065 - General disorders and administration site conditionsEUCTR2011-002222-46-NLRadboud University Nijmegen Medical Centre20
已完成
不适用
In vivo effects of C1-esterase inhibitor on innate immune response during endotoxemia in human - VECTOR II studyactivated immuun systemSystemic inflammation10027665NL-OMON39199niversitair Medisch Centrum Sint Radboud20
进行中（未招募）
1 期
Human pasteurized C1 esterase inhibitor concentrate (CE1145) in subjects with congenital C1-INH deficiency and acute abdominal or facial HAE attacks - C1-INH HAE studyHereditary angioedema (HAE) is characterized by congenital C1-INH deficiency. This is reflected by insufficient plasma concentrations of C1 – inhibitor or by synthesis of dysfunctional C1 – inhibitor molecules, which can lead to attacks of abdominal pain and/or severe swelling in the tissues e.g. of the face. Replacement with C1 esterase inhibitor concentrate is the treatment of choice of an acute attack of HAE.MedDRA version: 9.1Level: LLTClassification code 10019860Term: Hereditary angioedemaMedDRA version: 9.1Level: PTClassification code 10019860Term: Hereditary angioedemaEUCTR2004-001186-17-SECSL Behring GmbH126